Selecta In-Licenses Rights To IgG Protease Platform

by Vandana Singh, Benzinga Editor

October 21, 2021 9:50 AM | 1 min read |

Selecta Biosciences Inc SELB has announced a strategic licensing agreement to advance a next-generation IgG protease.
The partnership leverages Genovis' immunoglobulin G (IgG) protease, IdeXork (Xork), and Selecta's ImmTOR platform to enable the dosing of gene therapies and treat certain IgG-mediated autoimmune diseases.
Under the terms of the agreement, Selecta has provided Genovis with an upfront payment, while Genovis retains rights to research, preclinical, diagnostic, and other potential non-therapeutic applications of Xork.
Additionally, Genovis is eligible to earn development and sales-based milestones and tiered royalties on worldwide sales in the low double digits.
Specific deal terms were not disclosed.
Price Action: SELB shares are up 1.31% at $3.94 during the market session on the last check Thursday.

Posted In: Biotech News Penny Stocks Health Care Contracts Small Cap General autoimmune diseases Briefs gene therapy

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.